Aura Biosciences Inc
NASDAQ:AURA

Watchlist Manager
Aura Biosciences Inc Logo
Aura Biosciences Inc
NASDAQ:AURA
Watchlist
Price: 10.33 USD -3%
Market Cap: 512.5m USD
Have any thoughts about
Aura Biosciences Inc?
Write Note

Intrinsic Value

AURA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one AURA stock under the Base Case scenario is 4.56 USD. Compared to the current market price of 10.33 USD, Aura Biosciences Inc is Overvalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AURA Intrinsic Value
4.56 USD
Overvaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aura Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AURA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AURA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Aura Biosciences Inc

Provide an overview of the primary business activities
of Aura Biosciences Inc.

What unique competitive advantages
does Aura Biosciences Inc hold over its rivals?

What risks and challenges
does Aura Biosciences Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aura Biosciences Inc.

Provide P/S
for Aura Biosciences Inc.

Provide P/E
for Aura Biosciences Inc.

Provide P/OCF
for Aura Biosciences Inc.

Provide P/FCFE
for Aura Biosciences Inc.

Provide P/B
for Aura Biosciences Inc.

Provide EV/S
for Aura Biosciences Inc.

Provide EV/GP
for Aura Biosciences Inc.

Provide EV/EBITDA
for Aura Biosciences Inc.

Provide EV/EBIT
for Aura Biosciences Inc.

Provide EV/OCF
for Aura Biosciences Inc.

Provide EV/FCFF
for Aura Biosciences Inc.

Provide EV/IC
for Aura Biosciences Inc.

Show me price targets
for Aura Biosciences Inc made by professional analysts.

What are the Revenue projections
for Aura Biosciences Inc?

How accurate were the past Revenue estimates
for Aura Biosciences Inc?

What are the Net Income projections
for Aura Biosciences Inc?

How accurate were the past Net Income estimates
for Aura Biosciences Inc?

What are the EPS projections
for Aura Biosciences Inc?

How accurate were the past EPS estimates
for Aura Biosciences Inc?

What are the EBIT projections
for Aura Biosciences Inc?

How accurate were the past EBIT estimates
for Aura Biosciences Inc?

Compare the revenue forecasts
for Aura Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aura Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aura Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aura Biosciences Inc compared to its peers.

Compare the P/E ratios
of Aura Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aura Biosciences Inc with its peers.

Analyze the financial leverage
of Aura Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Aura Biosciences Inc.

Provide ROE
for Aura Biosciences Inc.

Provide ROA
for Aura Biosciences Inc.

Provide ROIC
for Aura Biosciences Inc.

Provide ROCE
for Aura Biosciences Inc.

Provide Gross Margin
for Aura Biosciences Inc.

Provide Operating Margin
for Aura Biosciences Inc.

Provide Net Margin
for Aura Biosciences Inc.

Provide FCF Margin
for Aura Biosciences Inc.

Show all solvency ratios
for Aura Biosciences Inc.

Provide D/E Ratio
for Aura Biosciences Inc.

Provide D/A Ratio
for Aura Biosciences Inc.

Provide Interest Coverage Ratio
for Aura Biosciences Inc.

Provide Altman Z-Score Ratio
for Aura Biosciences Inc.

Provide Quick Ratio
for Aura Biosciences Inc.

Provide Current Ratio
for Aura Biosciences Inc.

Provide Cash Ratio
for Aura Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Aura Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Aura Biosciences Inc?

What is the current Free Cash Flow
of Aura Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aura Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aura Biosciences Inc

Current Assets 195.6m
Cash & Short-Term Investments 187.4m
Other Current Assets 8.2m
Non-Current Assets 22.7m
PP&E 21.5m
Other Non-Current Assets 1.2m
Current Liabilities 10.5m
Accounts Payable 1.5m
Accrued Liabilities 8.3m
Other Current Liabilities 768k
Non-Current Liabilities 16.3m
Other Non-Current Liabilities 16.3m
Efficiency

Earnings Waterfall
Aura Biosciences Inc

Revenue
0 USD
Operating Expenses
-90.3m USD
Operating Income
-90.3m USD
Other Expenses
9.7m USD
Net Income
-80.7m USD

Free Cash Flow Analysis
Aura Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AURA Profitability Score
Profitability Due Diligence

Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Aura Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

AURA Solvency Score
Solvency Due Diligence

Aura Biosciences Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
80/100
Solvency
Score

Aura Biosciences Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AURA Price Targets Summary
Aura Biosciences Inc

Wall Street analysts forecast AURA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AURA is 22.44 USD with a low forecast of 20.2 USD and a high forecast of 24.15 USD.

Lowest
Price Target
20.2 USD
96% Upside
Average
Price Target
22.44 USD
117% Upside
Highest
Price Target
24.15 USD
134% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AURA?

Click here to dive deeper.

Dividends

Aura Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AURA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Aura Biosciences Inc Logo
Aura Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

512.2m USD

Dividend Yield

0%

Description

Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).

Contact

MASSACHUSETTS
Cambridge
85 Bolton St
+16175008864.0
www.aurabiosciences.com

IPO

2021-10-29

Employees

52

Officers

Founder, CEO, President & Director
Dr. Elisabet de los Pinos Ph.D.
Interim Principal Financial Officer & Interim Principal Accounting Officer
Ms. Amy Elazzouzi
Chief Technology Officer
Dr. Mark Plavsic D.V.M., Ph.D.
General Counsel & Secretary
Mr. Conor Kilroy
Senior Vice President of Clinical Development Operations
Mr. Patrick Nealon
VP & Therapeutic Area of Head Ocular Oncology
Dr. Anthony Daniels M.D.
Show More
Senior Vice President of Regulatory Affairs & Quality
Dr. Richard Mountfield Ph.D.
Chief Medical Officer & President of Research and Development
Dr. Jill J. Hopkins M.D.
Senior VP & Therapeutic Area Head of Urologic Oncology
Dr. Sabine Brookman-May
Show Less

See Also

Discover More
What is the Intrinsic Value of one AURA stock?

The intrinsic value of one AURA stock under the Base Case scenario is 4.56 USD.

Is AURA stock undervalued or overvalued?

Compared to the current market price of 10.33 USD, Aura Biosciences Inc is Overvalued by 56%.

Back to Top